Merck & Co Inc (NYSE:MRK)
| 81.94 Delayed Data As of Dec 04 |  +0.49 / +0.60%Today’s Change | 65.25 Today|||52-Week Range 92.64 | -9.91% Year-to-Date |
Latest MRK News | Press Releases
| Here's Why Biotech Deals Are All the Rage Right Now 8:45am / MotleyFool.com - Paid Partner Content | Encouraging News on COVID-19 Vaccine Dec 02 / Zacks.com - Paid Partner Content |
| Is It Too Late to Buy Moderna Stock? 7:25am / MotleyFool.com - Paid Partner Content | ADP Reports 307K New Jobs, Revisions Up Dec 02 / Zacks.com - Paid Partner Content |
| New Uses Could Boost Sales of Bristol-Myers and Merck Drugs Dec 04 / GuruFocus News - Paid Partner Content | Where Will Pfizer Be in 5 Years? Nov 28 / MotleyFool.com - Paid Partner Content |
| Should You Sell Your Moderna Stock Now? Dec 04 / MotleyFool.com - Paid Partner Content | Pharma Stock Roundup: AZN COVID-19 Vaccine Interim Data, PFE Emergency Use Appeal Nov 27 / Zacks.com - Paid Partner Content |
| Merck Just Sold Off Its Moderna Shares for a Huge Gain. Should You? Dec 03 / MotleyFool.com - Paid Partner Content | Why Moderna Is Less Risky Than You Think Nov 26 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 81.45 |
| Today’s open | 81.14 |
| Day’s range | 81.11 - 81.94 |
| Volume | 8,255,332 |
| Average volume (3 months) | 8,143,064 |
| Market cap | $202.0B |
Data as of 4:19pm ET, 12/04/2020
Growth & Valuation
| Earnings growth (last year) | +64.36% |
| Earnings growth (this year) | +14.77% |
| Earnings growth (next 5 years) | +8.60% |
| Revenue growth (last year) | +9.75% |
| P/E ratio | 18.1 |
| Price/Sales | 5.04 |
| Price/Book | 7.83 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| NVSNovartis | +1.37 | +1.52% |
| PFEPfizer | +0.26 | +0.65% |
| ABBVAbbVie | +2.53 | +2.42% |
| LLYEli Lilly and Co | +4.39 | +3.05% |
Data as of 6:25pm ET, 12/04/2020
Financials
| Next reporting date | February 4, 2021 |
| EPS forecast (this quarter) | $1.38 |
| Annual revenue (last year) | $46.6B |
| Annual profit (last year) | $9.8B |
| Net profit margin | 21.13% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Kenilworth, New Jersey |
Forecasts
